Targeted sequencing of BRCA1 and BRCA2 across a large unselected breast cancer cohort suggests that one-third of mutations are somatic
Christof Winter(TUM Klinikum), Lao H. Saal(Domos (Norway)), Matilda Rehn(Lund University), Åke Borg(Lund University), Y. Chen(Lund University), Johan Vallon‐Christersson(Lund University), Jari Häkkinen(Lund University), Martin Nilsson(Lund University), Anders Kvist(Lund University), Eric Olsson(Lund University), Martin Malmberg(Skåne University Hospital), Ulf Kristoffersson, Dorthe Grabau(Lund University), Sofia K. Gruvberger-Saal(Lund University), Göran Jönsson(Lund University), Anthony M. George(Lund University), Niklas Loman(Lund University), Therese Törngren(Lund University), Catharina Larsson(Lund University), Cecilia Hegardt(Lund University)
Cited by 152
Related Papers
Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies
|The American Journal of Human Genetics|2003|3.7k
Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks
|Nature Medicine|2001|2.7k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
|The Lancet|2010|2.3k
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k